STOCK TITAN

MetLife (NYSE: MET) director adds 17 deferred shares via plan

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

MetLife director Christian Stephane Mumenthaler acquired 17 shares of common stock as a grant under the MetLife Deferred Compensation Plan for Non-Management Directors. The award, recorded at a reference price of $70.60 per share, brings his directly held MetLife shares to 2,125.

Positive

  • None.

Negative

  • None.
Insider Mumenthaler Christian Stephane
Role Director
Type Security Shares Price Value
Grant/Award Common Stock 17 $70.60 $1K
Holdings After Transaction: Common Stock — 2,125 shares (Direct)
Footnotes (1)
  1. [object Object]
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Mumenthaler Christian Stephane

(Last) (First) (Middle)
METLIFE, INC.
200 PARK AVENUE

(Street)
NEW YORK NY 10166

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
METLIFE INC [ MET ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
03/10/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 03/10/2026 A(1) 17 A $70.6 2,125 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Imputed reinvestment of dividends on deferred shares pursuant to the MetLife Deferred Compensation Plan for Non-Management Directors. Deferred shares represent shares of MetLife, Inc. common stock that have become payable, but receipt of which the director has deferred.
Remarks:
/s/ Taylor McInerney Jansen, Attorney-in-fact 03/12/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did MetLife (MET) report for Christian Stephane Mumenthaler?

MetLife reported that director Christian Stephane Mumenthaler acquired 17 shares of common stock. The shares were granted as an imputed reinvestment of dividends on deferred shares under the MetLife Deferred Compensation Plan for Non-Management Directors.

Was the MetLife (MET) insider transaction a market purchase or a compensation grant?

The transaction was a compensation-related grant, not an open-market purchase. It reflects imputed reinvestment of dividends on deferred shares under MetLife’s Deferred Compensation Plan for Non-Management Directors, classified as a grant, award, or other acquisition.

How many MetLife (MET) shares did the director receive and at what price?

The director received 17 MetLife common shares, recorded at $70.60 per share. This figure represents the reference price for the awarded shares associated with the dividend reinvestment on deferred stock under the company’s non-management director compensation plan.

What are Christian Stephane Mumenthaler’s MetLife (MET) holdings after this Form 4 transaction?

After the reported grant, Christian Stephane Mumenthaler directly holds 2,125 MetLife common shares. This total includes the additional 17 shares credited through the dividend-based award under the MetLife Deferred Compensation Plan for Non-Management Directors.

What does the footnote in the MetLife (MET) Form 4 filing explain about the shares?

The footnote explains that the 17 shares reflect imputed reinvestment of dividends on deferred shares. These are payable MetLife common shares whose receipt the director has deferred under the MetLife Deferred Compensation Plan for Non-Management Directors.